Unique biopharmaceutical company with high barrier of entry, high growth expected, take the deal

QUICKNOTE: H1 Results in Line, R&D Pipeline Expands

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

<p>3SBio, a leading Chinese biotechnology company, plans to re-list in Hong Kong after de-listing from NASDAQ in 2013. The company's two main products, EPIAO and TPIAO, have leading market shares in their categories, and have promising growth prospects. The R&amp;D pipeline is extensive with many innovative, but early-stage compounds. &nbsp;The expected valuation at 25x projected 2016 earnings is a premium to most HK-listed pharma names which is justified by the superior visibility of the company's growth prospects.</p>

3SBio, a leading Chinese biotechnology company, plans to re-list in Hong Kong after de-listing from NASDAQ in 2013. The company's two main products, EPIAO and TPIAO, have leading market shares in their categories, and have promising growth prospects. The R&amp;D pipeline is extensive with many innovative, but early-stage compounds. &nbsp;The expected valuation at 25x projected 2016 earnings is a premium to most HK-listed pharma names which is justified by the superior visibility of the company's growth prospects.

A Leading Chinese Biotech Company, Quality Cornerstones, Take the Deal

3SBio Inc

A Leading Chinese Biotech Company, Quality Cornerstones, Take the Deal